Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Researchers evaluated the 12-year outcomes of the C9741 trial to identify patients most likely to benefit from dose-dense chemotherapy. They found that low endocrine activity in the cancer was a predictor of benefit.